connector

By using a connector with a specific structure to covalently link the carrier and the therapeutic molecule, the problem of high toxicity of existing conjugates is solved, and a conjugate that maintains therapeutic efficacy while reducing toxicity is realized, making it suitable for clinical application.

CN113453723BActive Publication Date: 2026-11-17OXFORD UNIVERSITY INNOVATION LTD +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN201980091603.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-08-09
Filing Date
2019-12-06
Publication Date
2026-11-17
Estimated Expiration
2039-12-06

AI Technical Summary

Technical Problem

Existing therapeutic conjugates have toxicity issues when delivering therapeutic molecules, making it difficult to maintain therapeutic efficacy while reducing toxicity.

Method used

A specific structure of linker is used to covalently link the carrier and the therapeutic molecule. The linker has a specific carbon chain length and orientation, which stabilizes the spatial orientation of the carrier and the therapeutic molecule, reduces the risk of enzymatic degradation, and reduces toxicity.

Benefits of technology

The toxicity of the carrier-therapeutic agent conjugate was significantly reduced, making the conjugate safer in clinical applications while maintaining therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0003202485130000091
    Figure BDA0003202485130000091
  • Figure BDA0003202485130000251
    Figure BDA0003202485130000251
Patent Text Reader

Abstract

This invention relates to linkers for attaching carrier molecules to therapeutic molecules to form conjugates, particularly linkers formed from amino acids such as glutamic acid, succinic acid, and γ-aminobutyric acid. The invention also relates to conjugates comprising the linkers of this invention, and the use of said conjugates in the treatment of a variety of diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to connectors for linking carrier molecules to therapeutic molecules to form conjugates. The invention also relates to conjugates comprising the connectors of this invention, and the use of said conjugates in the treatment of a variety of diseases. Background Technology

[0002] Therapeutic conjugates, which consist of a carrier molecule and a therapeutic molecule covalently linked together, were initially developed after it was recognized that therapeutic molecules often have poor cell penetration when used alone. The use of chaperone carriers is suggested to help cells take up therapeutic molecules into cells and / or tissues.

[0003] One such therapeutic group is the antisense oligonucleotide (ON). ON therapy has achieved rapid clinical progress in treating a variety of disease indications due to its targeting and high efficacy. ON can induce targeted regulation of pre-mRNA splicing, making it a particularly promising candidate for novel gene therapy drugs. It is especially useful for treating diseases caused by loss-of-function mutations, such as Duchenne muscular dystrophy (DMD). However, despite the broad applicability of ON compounds in treating many genetic diseases, their systemic administration has achieved only limited success in delivering therapeutic effects due to their poor penetration into target tissues and low levels of intracellular uptake.

[0004] To address the issue of poor intracellular absorption in oligonucleotide therapy, conjugates comprising carriers formed from short peptides have been developed. In recent years, cationic, positively charged cell-penetrating peptides (CPPs) have been used as carriers to facilitate the intracellular absorption of charge-neutral substances, such as therapeutic phosphoryldiamine morpholino oligomers (PMOs). CPP conjugates have been shown to successfully promote efficient intracellular absorption of PMOs in vivo in various disease models, including in the case of DMD.

[0005] However, the application of these carrier-therapeutic conjugates as treatments is hampered by their associated toxicities.

[0006] Amantana et al., Bioconjug Chem, 2007, 1325-1331, described dose-dependent toxicity of peptide-PMO conjugates. Toxicity exceeding a certain threshold was observed, including somnolence, rapid breathing, renal tubular degeneration, and weight loss. One such CPP conjugate, the B-PMO conjugate, has shown high acute toxicity in mdx mice (Wu et al., Am J Pathol, 2012, 392-400).

[0007] Work on reducing the toxicity of such therapeutic conjugates has primarily focused on developing delivery vectors (which are considered the source of toxicity). Regarding peptide delivery vectors, Wu et al., Nuc Acids Res, 2007, 35, 5182-5191, indicate that an increase in the number of 6-aminocaproic acid residues is associated with increased toxicity, and claim that this can be mitigated by optimizing arginine (R, D The position and number of arginine (R), aminocaproic acid (X), and β-alanine (B) residues can be used to design more active and stable CPPs. Other studies have further shown that the number or frequency of arginine residues in the peptide carrier negatively affects toxicity, therefore arginine residues should be reduced.

[0008] Vector peptides with various sequences have been developed in an attempt to reduce the toxicity of their conjugates, but many of these conjugates have not yet reached clinical use. This is either due to intolerable levels of toxicity or undesirable losses in efficacy. For example, Betts et al., Molecular Therapy-Nucleic Acids, 2012, 1, e38, demonstrate that some promising CPP vectors known in the art as “Pips” still do not possess an appropriate therapeutic index for clinical development. Furthermore, data contained in US 2016 / 0237426 indicate that other differently designed CPP vectors (e.g., R6Gly) do exhibit reduced toxicity, but their efficacy in inducing exon skipping is also reduced when used in conjugates containing therapeutic molecules.

[0009] Despite researchers’ efforts to modify the sequence of the vectors used in therapeutic conjugates, it has so far proven difficult to produce conjugates that simultaneously exhibit high efficacy in terms of therapeutic outcomes and acceptable levels of toxicity.

[0010] Therefore, conjugates are still needed to deliver therapeutic molecules that exhibit reduced toxicity while maintaining therapeutic efficacy when administered systemically to patients.

[0011] One or more aspects of the present invention are intended to at least solve this problem. Summary of the Invention

[0012] According to a first aspect of the invention, a conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, comprising at least one carrier, wherein the carrier is covalently linked to at least one linker, and wherein the linker is covalently linked to at least one therapeutic molecule; wherein each of the at least one linker independently has a structure according to formula (I):

[0013] -T1-(CR 1 R 2 ) n -T 2-

[0014] (I)

[0015] in

[0016] T1 is used for attachment to a carrier and is selected from -NH- or -C(O)-;

[0017] T2 is used to attach to the first therapeutic molecule and is selected from -NH- or -C(O)-;

[0018] n is an integer selected from 1, 2, or 3; and

[0019] R 1 Each time it appears, it is independently of the formula -Y. 1 -X 1 -Z 1 The groups, in which

[0020] Y 1 Does not exist or -[CR] A1 R A2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R A1 and R A2 Each is independently selected from hydrogen, OH, or (1-2C) alkyl;

[0021] X 1 The following do not exist or are -O-, -C(O)-, -C(O)O-, -OC(O)-, or -CH(OR) A3 )-、-N(R A3 )-、-N(R A3 -C(O)-、-N(R) A3 -C(O)O-、-C(O)-N(R) A3 )-、-N(R A3 )C(O)N(R A3 )-、-N(R A3 )C(NR A3 )N(R A3 )-, -SO-, -S--SO2-, -S(O)2N(R A3 - or -N(R) A3 SO2-, where R A3 Each is independently selected from hydrogen or methyl; and

[0022] Z 1It is another therapeutic molecule or selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl or heteroaryl, wherein the (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl or heteroaryl are each optionally substituted by one or more substituents selected from: (1-4C)alkyl, oxo, halogen, cyano, nitro, hydroxy, carboxyl, NR A4 R A5 Or (1-4C)alkoxy, where R A4 and R A5 Each is independently selected from hydrogen or (1-2C) alkyl; and

[0023] R 2 Each occurrence is independently of the formula -Y 2 -X 2 -Z 2 The groups, in which

[0024] Y 2 Does not exist or -[CR] B1 R B2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R B1 and R B2 Each is independently selected from hydrogen, OH, or (1-2C) alkyl;

[0025] X 2 The following do not exist or are -O-, -C(O)-, -C(O)O-, -OC(O)-, or -CH(OR) B3 )-、-N(R B3 )-、-N(R B3 -C(O)-、-N(R) B3 -C(O)O-、-C(O)-N(R) B3 )-、-N(R B3 )C(O)N(R B3 )-、-N(R B3 )C(NR B3 )N(R B3 )-, -SO-, -S--SO2-, -S(O)2N(R B3 - or -N(R) B3 SO2-, where R B3 Each is independently selected from hydrogen or methyl; and

[0026] Z 2The group is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl, wherein the (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl group is optionally substituted by one or more substituents selected from: (1-4C)alkyl, oxo, halogen, cyano, nitro, hydroxy, carboxyl, NR. B4 R B5 Or (1-4C)alkoxy, where R B4 and R B5 Each is independently selected from hydrogen or (1-2C) alkyl;

[0027] The condition is;

[0028] When n = 1 and T1 and T2 are different from each other, then R 1 and R 2 They are not both H;

[0029] When n=1, T1 and T2 are different from each other and R 1 and R 2 One of them is H, then R 1 and R 2 The other one is not methyl; or

[0030] When n = 2, and R 1 and R 2 If H appears every time, then T1 and T2 are both -C(O)- or both -NH-.

[0031] When the carrier is a peptide, the peptide is not glycosylated.

[0032] According to a second aspect of the invention, a conjugate according to the first aspect is provided for use as a medicine.

[0033] According to a third aspect of the invention, a pharmaceutical composition is provided comprising the conjugate according to the first aspect.

[0034] According to a fourth aspect of the invention, a pharmaceutical composition according to the third aspect is provided for use as a medicine.

[0035] The inventors have discovered that the linker located between the carrier and the therapeutic molecule within the conjugate has a striking effect on the toxicity of the conjugate.

[0036] If a linker is used within a conjugate, it is typically a small molecule, and its sole purpose is to link a carrier molecule to a therapeutic molecule. Until now, there has been no expectation or intention for the linker itself to play any role in the properties of the conjugate.

[0037] To the best of the inventors' knowledge, no study has been conducted on how the choice of connector affects the properties of the conjugate, and in particular, no study has been conducted on how the choice of connector affects the toxicity of the conjugate.

[0038] In this invention, the inventors investigated the effects of using different linkers on the toxicity of several peptide carrier conjugates. The inventors have identified several linkers that can positively improve the toxicity of therapeutic conjugates. Surprisingly, the inventors have found that linkers falling within the structural scope of the first aspect of this invention significantly reduce the toxicity of carrier-therapeutic agent conjugates compared to other linkers already used in the art.

[0039] Not bound by theory, and purely based on scientific speculation, the inventors believe that the linker falling within the scope of the first aspect of this invention possesses the ability to spatially align the carrier and therapeutic molecule, stabilizing and protecting them from protease cleavage. This could result in a reduced toxicity of the conjugate as a whole compared to similar conjugates using prior art linkers. This advantageous orientation could stem from the length of the carbon chain linking the carrier to the therapeutic molecule. The inventors believe that a specific carbon chain length provides sufficient distance between the carrier charge and the therapeutic molecule. Furthermore, the inventors believe that the metabolites generated upon degradation of said linker may be less toxic.

[0040] Advantageously, the discovery of linkers with this reduced toxicity means that previously developed and newly developed therapeutic conjugates are now available for use in the clinical setting. Furthermore, because linkers are separate from the carrier and therapeutic molecule, they can be readily used with different carriers and therapeutic molecules in many different conjugates without affecting the cell penetration of the carrier or the efficacy of the therapeutic molecule.

[0041] Certain features of any of the foregoing aspects of the invention will now be further defined under the headings below.

[0042] This invention includes any combination of the described aspects and features, unless such combination is obviously not permitted or explicitly avoided.

[0043] The chapter titles used in this article are for organizational purposes only and should not be construed as limiting the topics described.

[0044] connector

[0045] The connector is used to covalently link the carrier to the therapeutic molecule. The conjugate according to the invention comprises at least one connector defined by formula (I).

[0046] Appropriately, the aforementioned or each connector has a structure according to formula (I) as defined above, i.e.

[0047] -T1-(CR 1 R 2 )n -T 2-

[0048] (I)

[0049] In one embodiment, T1 is -NH-; in another embodiment, T1 is -C(O)-.

[0050] In one implementation, T2 is -C(O)-.

[0051] In one implementation, R1 appears independently of equation -Y each time. 1 -X 1 -Z 1 group,

[0052] in:

[0053] Y 1 Does not exist or -[CR] A1 R A2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R A1 and R A2 Each is independently selected from hydrogen or (1-2C) alkyl;

[0054] X 1 It does not exist or is -O-, -C(O)-, -C(O)O-, -N(R) A3 )-、-N(R A3 -C(O)-、-C(O)-N(R) A3 )-、-N(R A3 )C(O)N(R A3 )-、-N(R A3 )C(NR A3 )N(R A3 )- or -S-, where R A3 Each is independently selected from hydrogen or methyl; and

[0055] Z 1 It is another therapeutic molecule or selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl or heteroaryl.

[0056] The (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl groups are each optionally substituted by one or more substituents selected from the following: (1-4C)alkyl, oxo, halogen, cyano, nitro, hydroxy, carboxyl, NR. A4 R A5 Or (1-4C)alkoxy, where RA4 and R A5 Each is independently selected from hydrogen or (1-2C)alkyl.

[0057] In one implementation, R1 appears independently of equation -Y each time. 1 -X 1 -Z 1 The groups, wherein:

[0058] Y 1 Does not exist or -[CR] A1 R A2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R A1 and R A2 Each is independently selected from hydrogen or (1-2C) alkyl;

[0059] X 1 It does not exist or is -O-, -C(O)-, -C(O)O-, -N(R) A3 )-、-N(R A3 -C(O)-、-C(O)-N(R) A3 )-、-N(R A3 )C(O)N(R A3 )-、-N(R A3 )C(NR A3 )N(R A3 )- or -S-, where R A3 Each is independently selected from hydrogen or methyl; and

[0060] Z 1 Selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl.

[0061] The (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl groups are each optionally substituted by one or more substituents selected from the following: (1-4C)alkyl, oxo, halogen, cyano, nitro, hydroxy, carboxyl, NR. A4 R A5 Or (1-4C)alkoxy, where R A4 and R A5 Each is independently selected from hydrogen or (1-2C)alkyl.

[0062] In another implementation, R1 is independently of formula -Y each time it appears. 1 -X 1 -Z 1 The groups, wherein:

[0063] Y 1 Does not exist or -[CR] A1 R A2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R A1 and R A2 Each is independently selected from hydrogen or (1-2C) alkyl;

[0064] X 1 It does not exist or is -O-, -C(O)-, -C(O)O-, -N(R) A3 )-、-N(R A3 -C(O)-、-C(O)-N(R) A3 )-、-N(R A3 )C(O)N(R A3 )-、-N(R A3 )C(NR A3 )N(R A3 )- or -S-, where R A3 Each is independently selected from hydrogen or methyl;

[0065] Z 1 It is another therapeutic molecule or selected from hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl or heteroaryl, wherein the (1-6C)alkyl, aryl, (3-6C)cycloalkyl or heteroaryl are each optionally substituted by one or more substituents selected from (1-4C)alkyl, halogenated or hydroxyl.

[0066] In one implementation, R1 appears independently of equation -Y each time. 1 -X 1 -Z 1 The groups, wherein:

[0067] Y 1 Does not exist or -[CR] A1 R A2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R A1 and R A2 Each is independently selected from hydrogen or (1-2C) alkyl;

[0068] X 1 It does not exist or is -C(O)-, -C(O)O-, -N(R) A3 )-C(O)-、C(O)-N(R A3 )-, where R A3 Each is independently selected from hydrogen or methyl; and

[0069] Z 1It is another therapeutic molecule or selected from hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl or heteroaryl, wherein the (1-6C)alkyl, aryl, (3-6C)cycloalkyl or heteroaryl are each optionally substituted by one or more substituents selected from (1-4C)alkyl, halogenated or hydroxyl.

[0070] In one implementation, R1 appears independently of equation -Y each time. 1 -X 1 -Z 1 The groups, wherein:

[0071] Y 1 The expression either does not exist or is incorrect – [CH2] m - a group, where m is an integer selected from 1 or 2;

[0072] X 1 Does not exist or -N(R) A3 -C(O)-、-C(O)-N(R) A3 )-, where R A3 Each is independently selected from hydrogen.

[0073] or methyl; and

[0074] Z 1 It is hydrogen or (1-2C)alkyl.

[0075] In some implementations, Z 1 This can be a different therapeutic molecule, which may be the same as or different from the first therapeutic molecule linked to T2.

[0076] In one implementation, R2 appears independently of equation -Y each time. 2 -X 2 -Z 2 The groups, wherein:

[0077] Y 2 Does not exist or -[CR] A1 R A2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R A1 and R A2 Each is independently selected from hydrogen or (1-2C) alkyl;

[0078] X 2 It does not exist or is -O-, -C(O)-, -C(O)O-, -N(R) A3 )-、-N(R A3 -C(O)-、-C(O)-N(R) A3 )-、-N(R A3 )C(O)N(RA3 )-、-N(R A3 )C(NR A3 )N(R A3 )- or -S-, where R A3 Each is independently selected from hydrogen or methyl; and

[0079] Z 2 Selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl.

[0080] The (1-6C)alkyl, (2-6C)alkenyl, (2-6C)ynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl groups are each optionally substituted by one or more substituents selected from the following: (1-4C)alkyl, oxo, halogen, cyano, nitro, hydroxy, carboxyl, NR. B4 R B5 Or (1-4C)alkoxy, where R B4 and R B5 Each is independently selected from hydrogen or (1-2C)alkyl.

[0081] In one implementation, R 2 Each occurrence is independently of the formula -Y 2 -Z 2 The group, wherein: Y 2 Does not exist or is a formula – [CR] B1 R B2 ] m - groups, where m is an integer selected from 1, 2, 3 or 4, and R B1 and R B2 Each is independently selected from hydrogen or (1-2C) alkyl; and

[0082] Z 2 It is hydrogen or (1-6C) alkyl.

[0083] In a preferred embodiment, R 2 Each occurrence is H.

[0084] In some implementations, n is 1.

[0085] In some implementations, n is 2 or 3.

[0086] In one implementation, a conjugate as defined herein is provided having one of the following structures:

[0087]

[0088] In some embodiments, the linker is an amino acid or a derivative thereof. Therefore, the linker can be an amino acid or a modified amino acid that links the carrier to the therapeutic molecule. The amino acid can be modified to include a capping group (e.g., an acetyl capping group formed by capping with acetic anhydride) or a protecting group. Suitably, the capping group or protecting group can be present on the side chain of the amino acid.

[0089] Suitably, the amino acid can be linked to at least one carrier and at least one therapeutic molecule via at least two of the following: a side chain, an N-terminus, or a C-terminus. Suitably, the amino acid linker can be linked to at least one carrier via a side chain, an N-terminus, or a C-terminus. Suitably, the amino acid linker can be linked to at least one therapeutic molecule via a side chain, an N-terminus, or a C-terminus. For example, the amino acid linker can be linked to at least one carrier and at least one therapeutic molecule via an N-terminus and a side chain, a C-terminus and a side chain, or an N-terminus and a C-terminus, respectively. In one embodiment, the linker is an amino acid linked via both an N-terminus and a C-terminus. In one embodiment, the linker is an amino acid linked to the carrier via an N-terminus and to the therapeutic molecule via a C-terminus. In one embodiment, the linker is an amino acid linked to the carrier via a C-terminus and to the therapeutic molecule via an N-terminus. Suitably, the amino acid side chain can be linked to a second therapeutic molecule.

[0090] Suitablely, the linker may be an amino acid selected from the following: glutamic acid, aspartic acid, lysine, valine, leucine, histidine, tryptophan, threonine, serine, isoleucine, methionine, phenylalanine, and tyrosine, or derivatives thereof.

[0091] Suitably, the linker is glutamic acid or a derivative thereof. Suitably, the linker is glutamic acid or a derivative thereof found within the GABA branch. Suitably, the linker is selected from glutamic acid, succinic acid, or γ-aminobutyric acid (GABA).

[0092] In one embodiment, the connector is attached to the carrier via the N-terminus and to the GABA of the therapeutic molecule via the C-terminus.

[0093] In one embodiment, the connector is succinic acid linked to a therapeutic molecule via one of its carboxyl groups and to a carrier via another carboxyl group.

[0094] In one embodiment, the linker is glutamic acid, which is attached to the carrier via its N-terminus and to the therapeutic molecule via the side chain of the glutamic acid.

[0095] In one embodiment, the linker is glutamic acid, which is attached to the carrier via its C-terminus and to the therapeutic molecule via the side chain of glutamic acid.

[0096] definition

[0097] Always use "X" to represent any form of aminocaproic acid, such as 6-aminocaproic acid.

[0098] The amino acid β-alanine is always represented by "B".

[0099] The amino acid hydroxyproline is always represented by "[Hyp]".

[0100] The acetylation of the relevant peptide is always indicated by "Ac".

[0101] Amino acid residues whose genetic codes are based on recognized letter amino acid codes are always represented by uppercase letters.

[0102] In this specification, the term "alkyl" includes both straight-chain and branched alkyl groups. References to a single alkyl group (e.g., "propyl") refer only to the straight-chain form, while references to a single branched alkyl group (e.g., "isopropyl") refer only to the branched form. For example, "(1-6C)alkyl" includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl, and tert-butyl. Similar convention applies to other groups; for example, "phenyl(1-6C)alkyl" includes phenyl(1-4C)alkyl, benzyl, 1-phenylethyl, and 2-phenylethyl.

[0103] As used herein, the term "alkenyl" refers to an aliphatic group containing at least one double bond and is intended to include both "unsubstituted alkenyl" and "substituted alkenyl," the latter referring to a substituent having hydrogen atoms on one or more carbon atoms of the substituted alkenyl group. Such substituents may appear on one or more carbons contained in or not contained in one or more double bonds. For example, it is anticipated that the alkenyl group may be substituted with one or more alkyl, carbocyclic, aryl, heterocyclic, or heteroaryl groups.

[0104] As used herein, the term "alkynyl" refers to an aliphatic group containing at least one triple bond and is intended to include both "unsubstituted alkynyl" and "substituted alkynyl," the latter referring to a substituent on one or more carbon atoms of the alkynyl moiety having hydrogen atom. Such substituents may be present on one or more carbon atoms, either contained in or not contained in the triple bond. Furthermore, such substituents include all those contemplated herein.

[0105] The terms “(m-nC)” or “(m-nC) group” used alone or as a prefix refer to any group having m to n carbon atoms.

[0106] “(3-8C)cycloalkyl” refers to a hydrocarbon ring containing 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclic [2.2.1]heptyl.

[0107] "(3-8C)cycloalkenyl" refers to a hydrocarbon ring containing at least one double bond, such as cyclobutenyl, cyclopentenyl, cyclohexenyl, or cycloheptenyl (e.g., 3-cyclohexen-1-yl) or cyclooctenyl.

[0108] The term "halogenated" or "halogenated" refers to fluorinated, chlorinated, brominated, and iodinated compounds.

[0109] A “bridged ring system” refers to a ring system in which two rings share two or more atoms, see, for example, Advanced Organic Chemistry, Jerry March, 4th ed., Wiley Interscience, pp. 131-133, 1992. Examples of bridged heterocyclic systems include azabicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, azabicyclo[2.2.2]octane, azabicyclo[3.2.1]octane, and quinine rings.

[0110] The term "aryl" refers to an aromatic ring or polycyclic aromatic ring having 5 to 12 carbon atoms. The term aryl includes both monovalent and divalent substances. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, and naphthyl. In a particular embodiment, the aryl group is an optionally substituted phenyl group.

[0111] The term "heteroaryl" or "heteroaromatic" refers to an aromatic monocyclic, bicyclic, or polycyclic compound containing one or more (e.g., 1-4, particularly 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur. The term heteroaryl includes both monovalent and divalent compounds. Examples of heteroaryl groups are monocyclic and bicyclic groups containing five to twelve ring members, more typically five to ten. Heteroaryl groups can be, for example, 5- or 6-membered monocyclic or 9- or 10-membered bicyclic, such as bicyclic structures formed by fused five- and six-membered rings or two fused six-membered rings. Each ring may contain up to about four heteroatoms, typically selected from nitrogen, sulfur, and oxygen. Typically, a heteroaromatic ring will contain up to three heteroatoms, more typically up to two, such as a single heteroatom. In one embodiment, the heteroaromatic ring contains at least one cyclic nitrogen atom. The nitrogen atom in the heteroaromatic ring can be basic, as in the case of imidazole or pyridine, or substantially non-basic, as in the case of indole or pyrrole nitrogen. Typically, the number of basic nitrogen atoms present in a heteroaryl group (including any amino substituent in the ring) will be less than five.

[0112] Examples of heteroaryl groups include: furanyl, pyrrolyl, thiophenyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenoyl, benzofuranyl, indolyl, isoindolyl, benzothiophenyl, benzooxazolyl, benzoimidazolyl, benzothiazolyl, benzothiazolyl, indolyl, purinyl, benzofuranyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxolinyl Cinnamyl, pteridinyl, naphthidyl, carbazolyl, phenazinyl, benzisoquinoline, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furan[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazolo[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-b][1,2,4]triazinyl. "Heteroaryl" also includes bicyclic or polycyclic systems that are partially aromatic, wherein at least one ring is an aromatic ring, while one or more of the other rings are non-aromatic, saturated, or partially saturated rings, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen, or sulfur. Examples of heteroaryl groups that are partially aromatic include, for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzothiophene, dihydrobenzofuranyl, etc. 2,3-Dihydro-benzo[1,4]dioxacyclohexyl, benzo[1,3]dioxacyclopentane, 2,2-dioxo-1,3-dihydro-2-benzothiophene, 4,5,6,7-tetrahydrobenzofuranyl, dihydroindolyl, 1,2,3,4-tetrahydro-1,8-naphthidyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, and 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl.

[0113] Examples of five-membered heteroaryl groups include, but are not limited to, pyrrole, furanyl, thiophene, imidazolyl, furanyl, oxazolyl, oxadiazolyl, oxtriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl.

[0114] Examples of six-membered heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, pyridinyl, pyrimidinyl, and triazinyl.

[0115] The bicyclic heteroaryl group can be, for example, selected from the following groups:

[0116] A benzene ring fused with a 5- or 6-membered ring containing 1, 2, or 3 heteroatoms;

[0117] A pyridine ring fused with a 5- or 6-membered ring containing 1, 2, or 3 heteroatoms;

[0118] A pyrimidine ring fused with a 5- or 6-membered ring containing 1 or 2 heteroatoms;

[0119] Pyrrole rings fused with 5- or 6-membered rings containing 1, 2, or 3 heteroatoms;

[0120] A pyrazole ring fused with a 5- or 6-membered ring containing 1 or 2 heteroatoms;

[0121] A pyrazine ring fused with a 5- or 6-membered ring containing 1 or 2 heteroatoms;

[0122] An imidazole ring fused with a 5- or 6-membered ring containing 1 or 2 heteroatoms;

[0123] Oxazole rings fused with 5- or 6-membered rings containing 1 or 2 heteroatoms;

[0124] An isoxazole ring fused with a 5- or 6-membered ring containing 1 or 2 heteroatoms;

[0125] A thiazole ring fused with a 5- or 6-membered ring containing 1 or 2 heteroatoms;

[0126] An isothiazole ring fused with a 5- or 6-membered ring containing 1 or 2 heteroatoms;

[0127] Thiophene rings fused with 5- or 6-membered rings containing 1, 2, or 3 heteroatoms;

[0128] Furan rings fused with 5- or 6-membered rings containing 1, 2, or 3 heteroatoms;

[0129] Cyclohexyl rings fused with 5- or 6-membered heteroaromatic rings containing 1, 2, or 3 cyclic heteroatoms; and

[0130] A cyclopentyl ring fused with a 5- or 6-membered heteroaromatic ring containing 1, 2, or 3 cyclic heteroatoms.

[0131] Specific examples of bicyclic heteroaryl groups comprising a six-membered ring fused with a five-membered ring include, but are not limited to, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolazinyl, indolyl, isoindolyl, purine (e.g., adenine, guanine), indazole, benzodioxazolyl, and pyrazolopyridyl.

[0132] Specific examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolinyl, isoquinolinyl, benzodihydropyranyl, benzothiaranyl, benzopyranyl, isobenzopyranyl, benzodihydropyranyl, isobenzodihydropyranyl, benzodioxazinyl, quinolinyl, benzooxazinyl, benzodioxazinyl, pyridinylpyridinyl, quinoxalinyl, quinazolinyl, cinnamyl, phthalazinyl, naphthidyl, and pteridylyl.

[0133] The term "optionally substituted" refers to both substituted and unsubstituted groups, structures, or molecules. The term "wherein R..." 1 "Optional substitution of any CH, CH2, CH3 group or heteroatom (i.e., NH) within the group" appropriately refers to R 1 Any hydrogen group of the group is replaced by a group as specified in the relevant regulations.

[0134] When the optional substituent is selected from "one or more" groups, it should be understood that this definition includes all substituents selected from one of the specific groups or substituents selected from two or more specific groups.

[0135] carrier

[0136] The conjugates of the present invention contain a connector for linking a therapeutic molecule to a carrier molecule to form the conjugate.

[0137] Typically, carrier molecules facilitate the delivery of therapeutic molecules to their therapeutic targets, whether genes, transcripts, or proteins. Carriers can stabilize therapeutic molecules, ensuring their delivery to the target site without degradation. Similarly, carriers can promote the entry of therapeutic molecules into target cells.

[0138] Suitable carrier molecules can be used in the conjugates of the present invention. Suitable carriers include any biologically acceptable molecules, such as proteins, peptides, fatty acids, polymers, nanoparticles, and nucleic acid polymers.

[0139] In one embodiment, the carrier molecule is a peptide.

[0140] Appropriately, the carrier peptide can be linked to the adapter at either the N-terminus or the C-terminus of the carrier peptide.

[0141] Appropriately, in any of the structures disclosed herein, the peptide carrier can be linked to a therapeutic molecule via a linker at the N or C end of the peptide, and similarly, the therapeutic molecule can be linked via a linker at the N or C end of the peptide carrier.

[0142] Suitable peptide carriers are well known in the art. Such peptide carriers are described, for example, in GB1812972.6, GB1812980.9, WO2009 / 147368, WO2013 / 030569, and WO2009 / 005793.

[0143] Suitablely, if the carrier is a peptide, the peptide is not glycosylated. Suitablely, the carrier molecule is not a glycosylated peptide.

[0144] Appropriately, the length of the peptide carrier is at most 40 amino acids. Therefore, the peptide can be considered an oligopeptide.

[0145] Suitable, the total length of the peptide is 3-30 amino acid residues, suitablely 5-25 amino acid residues, 10-25 amino acid residues, 13-23 amino acid residues, or 15-20 amino acid residues.

[0146] Suitable, the total length of the peptide is at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 amino acid residues.

[0147] Appropriately, the peptide is capable of penetrating cells. Appropriately, the peptide can be considered a cell-penetrating peptide.

[0148] Suitablely, the sequence of the carrier peptide is a continuous single molecule, and therefore any domains of the peptide are continuous. Suitablely, the peptide may contain several domains arranged linearly between the N-terminus and C-terminus. Suitablely, the peptide carrier may contain any type of domain, such as hydrophobic, hydrophilic, cationic, anionic, neutral, acidic, or basic domains. Suitablely, the peptide carrier may contain any number of domains in any configuration.

[0149] The term "cation" as used in this article refers to an amino acid or amino acid domain that has an overall positive charge at physiological pH.

[0150] Appropriately, the isoelectric point (pI) of each cation domain is at least 7.5, at least 8.0, at least 8.5, at least 9.0, at least 9.5, at least 10.0, at least 10.5, at least 11.0, at least 11.5, or at least 12.0.

[0151] Appropriately, the isoelectric point (pI) of each cation domain is at least 10.0.

[0152] Appropriately, the isoelectric point (pI) of each cation domain is between 10.0 and 13.0.

[0153] Suitablely, the isoelectric point of the cation domain can be calculated at physiological pH using any suitable method available in the art. Suitablely, a network-based algorithm developed by Lukasz Kozlowski, BiolDirect. 2016; 11:55. DOI:10.1186 / s13062-016-0159-9 was used via IPC (www.isoelectric.org).

[0154] The term "hydrophobicity" as used in this article refers to amino acids or amino acid domains that have the ability to repel water or not mix with water.

[0155] Appropriately, the hydrophobicity of each hydrophobic structural domain is at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.7, at least 0.8, at least 0.8, at least 1.0, at least 1.1, at least 1.2, or at least 1.3.

[0156] Appropriately, the hydrophobicity of each hydrophobic structural domain is between 0.4 and 1.4.

[0157] Appropriately, hydrophobicity was measured by White and Wimley: WC Wimley and SH White, "Experimentally determined hydrophobicity scale for proteins at membrane interfaces" Nature Struct Biol 3:842 (1996).

[0158] Suitably, the peptide carrier may comprise or consist of hydrophobic and / or cationic domains. Suitably, the peptide carrier comprises at least one cationic domain and at least one hydrophobic domain. Suitably, the peptide carrier comprises two cationic domains and one hydrophobic domain.

[0159] Suitably, the cationic domain is located at the N and C ends of the peptide carrier. Suitably, at either end of the peptide carrier. Suitably, one or more hydrophobic domains are located at the center of the peptide carrier. Suitably, the hydrophobic domains separate any two cationic domains. Suitably, each hydrophobic domain is side-attached to a cationic domain on either side. Suitably, no cationic domain is adjacent to another cationic domain.

[0160] Appropriately, each domain has a length of 3-15 amino acid residues. Appropriately, a length of 3-7 amino acid residues. Appropriately, each domain of the same type has a similar length. Appropriately, each domain of the same type has the same length. Appropriately, each cationic domain has a length of 4, 5, 6, or 7 amino acid residues.

[0161] Appropriately, each hydrophobic domain has a length of 3-6 amino acids. Appropriately, each hydrophobic domain has a length of 5 amino acids.

[0162] Appropriately, the peptide carrier is a positively charged peptide.

[0163] Suitably, the peptide carrier is an arginine-rich peptide. Suitably, the peptide carrier contains at least 20%, 30%, at least 32%, at least 34%, at least 36%, at least 38%, at least 40%, at least 42%, at least 44%, at least 46%, at least 48%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% arginine residues. Suitably, the peptide carrier contains a majority of arginine residues.

[0164] Suitablely, the peptide carrier may not contain artificial amino acids. Suitablely, the peptide carrier may not contain aminocaproic acid residues. The term "artificial" amino acid or residue as used herein refers to any amino acid that is not naturally occurring, and includes synthetic amino acids, modified amino acids (e.g., amino acids modified with sugars), non-natural amino acids, artificial amino acids, spacers, and non-peptide-bonded spacers.

[0165] Synthetic amino acids can be those that are chemically synthesized by humans.

[0166] To avoid any ambiguity, in the context of this invention, aminocaproic acid (X) is an artificial amino acid.

[0167] Appropriately, the cation domain is positively charged.

[0168] Suitably, the cationic domain is rich in arginine. Suitably, each cationic domain contains a majority of arginine residues. Suitably, the cationic domain contains at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 60%, at least 65%, at least 70%, at least 80%, or at least 90% arginine residues. Suitably, each cationic domain contains 40-70% arginine residues.

[0169] Suitablely, each hydrophobic domain contains a majority of hydrophobic amino acid residues. Suitablely, each hydrophobic domain contains at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% hydrophobic amino acids. Suitablely, each hydrophobic domain is composed of hydrophobic amino acid residues.

[0170] Suitablely, each cationic domain has at least 3 arginine residues, suitablely at least 4 arginine residues. Suitablely, each cationic domain contains 4, 5, 6 or more arginine residues. Suitablely, the cationic domain contains no more than 3 consecutive arginine residues, suitablely no more than 2 consecutive arginine residues.

[0171] Suitable, the cation domain comprises amino acid units selected from the following: RBR, RXR, XXR, XRR, RRX, BXR, RXB, XRB, RBB, BRB, BBR, RRB, BRR, and BRXR, H, B, RR, HH, BB, RH, HR, RB, BR, HB, BH, RBR, RBB, BRR, BBR, BRB, RBH, RHB, HRB, BRH, HRR, RRH, HRH, HBB, BBH, RHR, BHB, HBH, or any combination thereof.

[0172] Suitable, the cationic domain is formed from amino acid units selected from the following: R, RR, RJR, RRJ, JRR in any combination or sequence. Wherein J represents any non-natural amino acid.

[0173] Suitablely, the cation domain may comprise (RXR)n, where n = 2, 3 or 4; [SEQ ID NOs: 1-3] and / or (RBR)n, where n = 2, 3 or 4; [SEQ ID NOs: 4-6] and / or (RHR)n, where n = 2, 3 or 4 [SEQ ID NOs: 7-9], or a combination thereof.

[0174] Suitablely, the cationic domain may also include serine, proline, and / or hydroxyproline residues. Suitablely, the cationic domain may further comprise an amino acid unit selected from: RP, PR, PP, RPR, RRP, PRR, PRP, Hyp; R[Hyp]R, RR[Hyp], [Hyp]RR, [Hyp]R[Hyp], [Hyp][Hyp]R, R[Hyp][Hyp], SB, BS, or any combination thereof, or any combination with the amino acid units listed above.

[0175] Suitable, the hydrophobic domain may comprise one of the following sequences: ZAA, ZA, Z, AZA, AZ, ZAZ, ZZA, and ZZZ; wherein Z represents a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (TIC) residue. A represents a hydrophobic amino acid residue as defined above.

[0176] Suitablely, the hydrophobic domain is selected from one of the following sequences: GFTGPL (SEQ ID NO. 10), QFL, Z, ZL, F, FL, FQILY (SEQ ID NO. 11), FQ, WF, QF, FQ, and YQFLI (SEQ ID NO. 12). Suitablely, the core domain is selected from one of the following sequences: Z, F, and FL, or any combination thereof. Wherein Z represents a 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (TIC) residue.

[0177] Suitablely, the or each hydrophobic structural domain comprises one of the following sequences: YQFLI (SEQ ID NO:12), FQILY (SEQ ID NO:11), ILFQY (SEQ ID NO:13), FQIY (SEQ ID NO:14), WWW, WWPWW (SEQ ID NO:15), WPWW (SEQ ID NO:16), WWPW (SEQ ID NO:17), ILFQ (SEQ ID NO:18), ILIQ (SEQ ID NO:19), IKILFQN (SEQ ID NO:20), IHILFQN (SEQ ID NO:21), IRILFQN (SEQ ID NO:22), IILFQN (SEQ ID NO:23), KILFQN (SEQ ID NO:24), HILFQN (SEQ ID NO:25), RILFQN (SEQ ID NO:26), ILFQN (SEQ ID NO:27), HLIQN (SEQ ID NO:28), KILIQN (SEQ ID NO:19). 29), KILIQY (SEQ ID NO:30), HILIQN (SEQ ID NO:31), RILIQN (SEQ ID NO:32), HILIQY (SEQ ID NO:33), RILIQY (SEQ ID NO:34), ILIQN (SEQ ID NO:35), ILIQY (SEQ ID NO:36) or any combination thereof, or any combination with the amino acid units listed above.

[0178] Suitable, the peptide carrier may consist of one of the following sequences:

[0179] RRRRR (SEQ ID NO:37)

[0180] RRRRRR (SEQ ID NO:38)

[0181] RRRRRRR (SEQ ID NO:39)

[0182] RRRRRRRR (SEQ ID NO:40)

[0183] (RXRRBR)2 (SEQ ID NO:41)

[0184] RXRRBRRXRRBRX (SEQ ID NO:42)

[0185] RXRRXRRXRRXRX (SEQ ID NO:43)

[0186] RXRRBRRFQILYRBRXR (SEQ ID NO:44)

[0187] RXRRBRRXRILFQYRXRBRXR (SEQ ID NO:45)

[0188] RXRRBRRXRILFQYRXRXRXR (SEQ ID NO:46)

[0189] RXRRXRILFQYRXRRXR (SEQ ID NO:47)

[0190] RBRRXRRBRILFQYRBRXRBR (SEQ ID NO:48)

[0191] RBRRXRRBRILFQYRXRBRXR (SEQ ID NO:49)

[0192] RBRRXRRBRILFQYRXRRXR (SEQ ID NO:50)

[0193] RBRRXRRBRILFQYRXRBRX (SEQ ID NO:51)

[0194] RXRRBRRXRILFQYRXRRXR (SEQ ID NO:52)

[0195] RXRRBRRXRILFQYRXRBRX (SEQ ID NO:53)

[0196] RXRRBRRXRILFQYRXRBRXR (SEQ ID NO:54)

[0197] RXRRBRRXRYQFLIRXRBRXR (SEQ ID NO:55)

[0198] RXRRBRRXRIQFLIRXRBRXR (SEQ ID NO:56)

[0199] RXRRBRRXRQFLIRXRBRXR (SEQ ID NO:57)

[0200] RXRRBRRXRQFLRXRBRXR (SEQ ID NO:58)

[0201] RXRRBRRXYRFLIRXRBRXR (SEQ ID NO:59)

[0202] RXRRBRRXRFQILYRXRBRXR (SEQ ID NO:60)

[0203] RXRRBRRXYRFRLIXRBRXR (SEQ ID NO:61)

[0204] RXRRBRRXILFRYRXRBRXR (SEQ ID NO:62)

[0205] RXRRBRRXRIYQFLIRXRBRXR (SEQ ID NO:63)

[0206] Suitable, the peptide carrier may consist of one of the following sequences:

[0207] YQFLIRBRRXRBRXBRXRBYQFLI (SEQ ID NO:64)

[0208] YQFLIRBRRBRBRRBYQFLI (SEQ ID NO:65)

[0209] YQFLIRBRRBRBRBRBBRXRBYQFLI (SEQ ID NO:66)

[0210] Suitable, the peptide carrier may consist of one of the following sequences:

[0211] RBRRBRRFQILYRBRBR (SEQ ID NO:67)

[0212] RBRRBRRYQFLIRBRBR (SEQ ID NO:68)

[0213] RBRRBRRILFQYRBRBR (SEQ ID NO:69)

[0214] RBRRBRFQILYBRBR (SEQ ID NO:70)

[0215] RBRRBRRFQILYRBHBH (SEQ ID NO:71)

[0216] RBRRBRRFQILYHBHBR (SEQ ID NO:72)

[0217] RBRRBRFQILYRBHBH (SEQ ID NO:73)

[0218] Suitably, the peptide carrier is N-terminally modified. Suitably, the peptide carrier is N-acetylated, N-methylated, N-trifluoroacetylated, N-trifluoromethanesulfonated, or N-methanesulfonated, or modified with additional fatty acids. Suitably, the peptide carrier is N-acetylated.

[0219] Optionally, the N-terminus of the peptide carrier may be unmodified.

[0220] In one embodiment, the peptide carrier is N-acetylated.

[0221] Suitablely, the carrier is covalently bonded to the connector. Suitablely, the connector can be covalently bonded to the carrier via amide, ester, ether, disulfide, or thioether bonds. Suitablely, the carrier is connected to the connector via amide or ester bonds.

[0222] Therapeutic molecules

[0223] The conjugates of the present invention comprise therapeutic molecules linked to carrier molecules to form the conjugates, the conjugates facilitating the delivery of therapeutic molecules to relevant therapeutic targets.

[0224] The therapeutic molecule can be any molecule used to treat a disease. The therapeutic molecule can be selected from: nucleic acids, peptide nucleic acids, oligonucleotides, antisense oligonucleotides (e.g., PNA, PMO), mRNA, gRNA (e.g., when using CRISPR / Cas9 technology), short interfering RNA, microRNA, antagomiRNA, peptides, cyclic peptides, proteins, pharmaceuticals, drugs, or nanoparticles.

[0225] Therapeutic proteins can be selected from: antibodies, antigens, VH domains, VL domains, scFv molecules, Fc moieties, receptors or their extracellular domains, Fab, and receptor-binding portions of ligands, enzymes, growth factors, interleukins, cytokines, and chemokines.

[0226] Suitablely, the therapeutic molecule is a nucleic acid. Suitablely, the therapeutic molecule is an oligonucleotide, which may be an antisense oligonucleotide.

[0227] The therapeutic nucleic acid sequence can be selected from any available sequence, for example, an antisense oligonucleotide for exon skipping in DMD, described at https: / / research-repository.uwa.edu.au / en / publications / antisense-oligonucleotide-induced-exon-skipping-across-the-human, or a therapeutic antisense oligonucleotide complementary to the ISSN1 or IN7 sequence for treating SMA, described at Zhou, HGT, 2013; and Hammond et al., 2016; and Osman et al., HMG, 2014. In one embodiment, the therapeutic molecule is an antisense oligonucleotide.

[0228] Suitable, the antisense oligonucleotide is composed of phosphoryldiamine morpholino oligonucleotide (PMO).

[0229] Alternatively, the oligonucleotide may be a modified PMO or any other charge-neutral oligonucleotide, such as peptide nucleic acid (PNA), chemically modified PNA such as γ-PNA (Bahal, Nat. Comm. 2016), oligonucleotide aminophosphate (where the non-bridging oxygen of the phosphate group is replaced by an amine or alkylamine) as described in WO2016028187A1, or any other partially or completely charge-neutral oligonucleotide.

[0230] In one embodiment, the therapeutic molecule of the conjugate is an oligonucleotide complementary to the pre-mRNA of the gene target. In another embodiment, the therapeutic molecule is siRNA.

[0231] In appropriate cases, oligonucleotides complementary to the pre-mRNA of a gene target induce steric hindrance events, which alter the pre-mRNA, leading to altered mRNA and consequently altered protein sequence.

[0232] Suitablely, the steric blocking event can be exon inclusion or exon skipping. In one embodiment, the steric blocking event is exon skipping. Suitablely, the therapeutic molecule is an oligonucleotide sequence for inducing exon skipping. Suitablely, the therapeutic molecule is an oligonucleotide sequence capable of inducing exon skipping of one or more exons.

[0233] Suitablely, the therapeutic molecule is used to treat genetic diseases. Suitablely, the therapeutic molecule is used to treat hereditary genetic diseases. Suitablely, the therapeutic molecule is used to treat hereditary X-linked genetic diseases.

[0234] Suitablely, the therapeutic molecule is used to treat inherited neuromuscular diseases. Suitablely, the therapeutic molecule is used to treat genetic diseases of the neuromuscular system. Suitablely, the therapeutic molecule is used to treat hereditary diseases of the neuromuscular system. Suitablely, the therapeutic molecule is used to treat hereditary neuromuscular diseases. Suitablely, the therapeutic molecule is used to treat hereditary X-linked diseases of the neuromuscular system. Suitablely, the therapeutic molecule is used to treat hereditary X-linked neuromuscular diseases.

[0235] Appropriately, in any of the above embodiments, the therapeutic molecule is a nucleic acid, appropriately an oligonucleotide, and appropriately an antisense oligonucleotide.

[0236] Suitablely, the therapeutic molecule is used to treat DMD. Suitablely, the therapeutic molecule used to treat DMD is a nucleic acid, and suitablely, an antisense oligonucleotide.

[0237] Appropriately, the antisense oligonucleotide sequence is used to induce exon skipping in the dystrophin gene for the treatment of DMD.

[0238] In one embodiment, the antisense oligonucleotide sequence is used to induce exon skipping of a single exon of the dystrophin gene for the treatment of DMD. Suitably, the single exon is selected from any exon associated with DMD, which can be any exon of the dystrophin gene, such as exon 45, 51, or 53. Suitably, the medical use of the therapeutic molecule is the same as the medical use of the conjugate containing the therapeutic molecule. Therefore, suitably, any medical use described herein in relation to the therapeutic molecule is equally applicable to the conjugates of the present invention.

[0239] PMO oligonucleotides of any sequence can be purchased (e.g., from Gene Tools Inc., USA).

[0240] Optionally, lysine residues may be added to one or both ends of a therapeutic molecule (such as PMO or PNA) before attachment to the peptide to improve water solubility.

[0241] Suitable, the molecular weight of the therapeutic molecule is less than 5000 Da, suitable, less than 3000 Da, or suitable, less than 1000 Da.

[0242] Imaging molecules

[0243] The conjugates of the present invention may also contain imaging molecules linked to carrier molecules to provide the conjugates.

[0244] The imaging molecule can be any molecule capable of visualizing the conjugate. Suitably, the imaging molecule can indicate the location of the conjugate. Suitably, the location of the conjugate is in vitro or in vivo. Suitably, a method for monitoring the location of a conjugate containing an imaging molecule is provided, the method comprising: applying the conjugate to a subject and imaging the subject to locate the conjugate.

[0245] Examples of imaging molecules include detection molecules, contrast molecules, or enhancement molecules. Suitable imaging molecules may be selected from radionuclides; fluorophores; nanoparticles (e.g., nanoshells); nanocages; chromophores (e.g., enzymes); radioisotopes; dyes; radiopaque materials; fluorescent compounds; and combinations thereof.

[0246] Appropriately, imaging techniques are used to visualize the imaging molecules; these techniques may be cellular imaging techniques or medical imaging techniques. Appropriate cellular imaging techniques include, for example, imaging flow cytometry, fluorescence microscopy, phase contrast microscopy, SEM, and TEM. Appropriate medical imaging techniques include, for example, X-ray, fluorescence examination, MRI, scintillation scanning, SPECT, PET, CT, CAT, and FNRI.

[0247] In some cases, the imaging molecule can be considered a diagnostic molecule. Suitablely, the diagnostic molecule can be used to diagnose diseases using the conjugate. Suitablely, the diagnosis of a disease can be achieved by using the imaging molecule to determine the location of the conjugate. Suitablely, a method for diagnosing a disease is provided, the method comprising applying an effective amount of a conjugate containing an imaging molecule to a subject and monitoring the location of the conjugate.

[0248] Appropriately, the details of the connectors of conjugates containing imaging molecules are the same as those described above for conjugates containing therapeutic molecules.

[0249] Suitable, the conjugate can penetrate into cells and tissues, and suitablely into the cell nucleus. Suitablely, it can enter muscle tissue.

[0250] Conjugate

[0251] The conjugates of the present invention comprise at least one carrier connected to at least one therapeutic molecule using at least one connector as defined in the first aspect.

[0252] Suitablely, the connectors of the present invention can be used to attach a carrier to one or more therapeutic molecules to provide a conjugate. Therefore, suitablely, one or more connectors of the present invention can be used to attach a carrier to one or more therapeutic molecules.

[0253] Suitably, the carrier is linked to at least one therapeutic molecule via at least one connector. Therefore, suitably, the conjugates of the present invention comprise a carrier linked to at least one therapeutic molecule via at least one connector.

[0254] Appropriately, the conjugate may contain more than one connector and / or more than one therapeutic molecule.

[0255] In one embodiment, the conjugate comprises a carrier covalently linked to a therapeutic molecule via a linker. Suitably, the conjugate may comprise or consist of the following structures:

[0256] [Carrier]–[Connector]–[Therapeutic Molecule]

[0257] Suitable, the carrier can be linked to two therapeutic molecules. In such embodiments, the conjugate may comprise a carrier covalently linked to two therapeutic molecules via a connector. Suitable, the conjugate may comprise or consist of the following structures:

[0258]

[0259] Alternatively, the conjugate may comprise a carrier covalently linked to two therapeutic molecules via two linkers. Suitable, the conjugate may comprise or consist of the following structures:

[0260]

[0261] Alternatively, the conjugate may contain or be composed of the following structures:

[0262] [Therapeutic molecule]–[Connector]–[Carrier]–[Connector]–[Therapeutic molecule]

[0263] Suitablely, the conjugate may contain more than one carrier. Suitablely, each carrier is covalently linked by a linker. Suitablely, no two carriers are contiguous. Suitablely, the conjugate may contain two carriers. Therefore, suitablely, the conjugate may contain a first carrier and a second carrier, which are suitablely linked by a first linker and a second linker. Suitablely, each carrier may be the same or different. Suitablely, each linker may be the same or different. Suitablely, each carrier may have a specific function. Suitablely, at least one carrier has the function of cell penetration. However, other carrier functions may include receptor binding, enzyme activation, enzyme inhibition, solubility regulation, half-life regulation, indication, detection, stability regulation, conformation or orientation regulation, etc.

[0264] In one embodiment, the conjugate comprises a first carrier covalently linked to a second carrier via a first connector, the second carrier being covalently linked to a second connector, and the second connector being covalently linked to a therapeutic molecule.

[0265] Appropriately, the conjugate may contain or consist of the following structures:

[0266] [Carrier]–[Connector]–[Carrier]–[Connector]–[Therapeutic Molecule]

[0267] In one implementation, the first carrier has cell-penetrating capabilities, while the second carrier has receptor-binding capabilities.

[0268] Suitablely, the conjugates of the present invention can exist in any orientation. Therefore, suitablely, the conformation of the above-described conjugates can be reversed.

[0269] Suitably, in any of the above embodiments, the therapeutic molecule may be replaced by an imaging molecule. Suitably, in any of the above embodiments, the conjugate may also comprise one or more imaging molecules. Suitably, the imaging molecule may be connected to the therapeutic molecule, or the carrier may be connected via other connectors. Suitably, the other connectors may be connectors of the present invention. Suitably, the connectors and any other connectors may be the same or different.

[0270] Suitablely, any of the carriers listed herein may be used in the conjugates according to the invention. Suitablely, any of the therapeutic molecules listed herein may be used in the conjugates according to the invention.

[0271] Pharmaceutical Composition

[0272] The conjugates of the present invention can be formulated into pharmaceutical compositions for delivery to subjects in need.

[0273] Suitable of the pharmaceutical composition, the composition comprises the conjugate of the present invention.

[0274] Suitable, the pharmaceutical composition may further comprise a pharmaceutically acceptable diluent, adjuvant, or carrier.

[0275] Appropriate pharmaceutically acceptable diluents, adjuvants, and carriers are well known in the art.

[0276] As used herein, the phrase “pharmaceutically acceptable” means that ligands, materials, formulations, and / or dosage forms are suitable for contact with human and animal tissues, within reasonable medical judgment, without excessive toxicity, irritation, allergic reactions, or other problems or complications, and that meet a reasonable benefit / risk ratio.

[0277] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, formulation, or medium, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulation material, relating to carrying or transporting the conjugate from one organ or site of the body to another organ or site of the body. Each cell-penetrating peptide must be "acceptable," for example, peptides and therapeutic molecules, and harmless to the individual, in the sense of compatibility with the other components of the composition. Reconstituteable and administerable lyophilized compositions are also within the scope of the compositions of this invention.

[0278] Pharmaceutically acceptable carriers can be, for example, excipients, mediators, diluents, and combinations thereof. For example, when the compositions are administered orally, they can be formulated as tablets, capsules, granules, powders, or syrups; or for parenteral administration, they can be formulated as injections, infusions, nebulizers, aerosols, or suppositories. These compositions can be prepared by conventional methods, and if desired, the active compound (i.e., the conjugate) can be mixed with any conventional additives, such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspending agents, emulsifiers, coating agents, or combinations thereof.

[0279] It should be understood that the pharmaceutical compositions disclosed herein may further include other known therapeutic agents, drugs, compounds modified into prodrugs, etc., for use in medical purposes to alleviate, regulate, prevent and treat the diseases, symptoms and conditions described herein.

[0280] Suitablely, the pharmaceutical composition is used as a medicine. Suitablely, it is used as a medicine in the same manner as the conjugates described herein. All characteristics described herein relating to medical treatment using the conjugates are applicable to the pharmaceutical composition.

[0281] On the other hand, a method for treating a disease or condition in a subject in need is provided, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to the third aspect.

[0282] Medical use

[0283] The conjugates of the present invention can be used as drugs to treat diseases.

[0284] The drug may be in the form of a pharmaceutical composition as defined above.

[0285] In another aspect, a method for treating a disease or condition in a subject in need is also provided, the method comprising the step of administering a therapeutically effective amount of the conjugate according to the first aspect to the subject.

[0286] Appropriately, medical treatment requires the delivery of the therapeutic molecule into tissues or cells, appropriately into the nucleus of the cell, or appropriately after systemic injection.

[0287] The disease to be treated can include any disease in which improved penetration of the therapeutic molecule into the cell and / or nuclear membrane can lead to improved therapeutic effects.

[0288] Appropriately, conjugates are used to treat diseases as defined by the therapeutic use of the therapeutic molecule.

[0289] Suitably, conjugates containing the connector of the present invention are suitable for treating genetic diseases. Suitably, conjugates containing the connector of the present invention are suitable for treating hereditary genetic diseases. Suitably, conjugates containing the connector of the present invention are suitable for treating hereditary X-linked genetic diseases. Suitably, the conjugates are used to treat diseases of the neuromuscular system. Suitably, conjugates containing the connector of the present invention are suitable for treating genetic diseases of the neuromuscular system. In a suitable embodiment, a conjugate according to the first aspect is provided for treating genetic diseases of the neuromuscular system.

[0290] Suitablely, the conjugate is used to treat hereditary diseases of the neuromuscular system. Suitablely, the conjugate is used to treat hereditary neuromuscular diseases. Suitablely, the conjugate is used to treat hereditary X-linked diseases of the neuromuscular system. Suitablely, the conjugate is used to treat hereditary X-linked neuromuscular diseases.

[0291] Suitablely, the conjugate is used to treat diseases caused by splicing defects. In such embodiments, the therapeutic molecule may comprise an oligonucleotide as described above, capable of preventing or correcting splicing defects and / or increasing the production of correctly spliced ​​mRNA molecules. Suitablely, in such embodiments, the therapeutic molecule is an antisense oligonucleotide as described above.

[0292] Suitablely, the conjugate is used to treat any of the following diseases: Duchenne muscular dystrophy (DMD), Bucher muscular dystrophy (BMD), Menkes disease, β-thalassemia, dementia, Parkinson's disease, spinal muscular atrophy (SMA), Huntington's disease, Hutchinson-Gilford progeria, ataxia-telangiectasia, or cancer.

[0293] In one embodiment, the conjugate is used to treat DMD. In one embodiment, a conjugate according to the first aspect is provided for treating DMD.

[0294] Suitably, in such embodiments, the therapeutic molecule of the conjugate is operable to restore the reading frame of the dystrophic transcript. Suitably, the therapeutic molecule of the conjugate is operable to induce the production of internally truncated partially functional myotrophins. Suitably, in such embodiments, the therapeutic molecule is an antisense oligonucleotide as described in the relevant sections above. Suitably, the patient or subject to be treated can be any animal or human. Suitably, the patient or subject can be a non-human mammal. Suitably, the patient or subject can be male or female. In one embodiment, the subject is male.

[0295] Appropriately, the patient or subject to be treated can be of any age. Appropriately, the age of the patient or subject to be treated is 0-40 years, appropriately 0-30 years, appropriately 0-25 years, or appropriately 0-20 years.

[0296] Suitable, the conjugate is used for systemic administration to a subject, for example, via intramedullary, intrasheath, intravenous, intravitreal, enteric, parenteral, intravenous, intraarterial, intramuscular, intratumoral, intracranial, intraventricular, subcutaneous, oral, or intranasal routes.

[0297] In one embodiment, the conjugate is administered intravenously to a subject.

[0298] In one embodiment, the conjugate is administered to a subject by injection.

[0299] Appropriately, the conjugate is administered to the subject in a “therapeuticly effective amount,” which means that the amount is sufficient to demonstrate benefit to the individual. The actual amount administered, as well as the rate and timing of administration, will depend on the nature and severity of the disease being treated. The determination of dosage is the responsibility of the general practitioner and other physicians. Examples of this technique and protocol can be found in Remington's Pharmaceutical Sciences, 20th Edition, 2000, pub. Lippincott, Williams & Wilkins.

[0300] Exemplary doses may be any value between 0.01 mg / kg and 200 mg / kg, between 0.05 mg / kg and 160 mg / kg, between 0.1 mg / kg and 140 mg / kg, between 0.5 mg / kg and 120 mg / kg, between 1 mg / kg and 100 mg / kg, between 2 mg / kg and 80 mg / kg, between 5 mg / kg and 60 mg / kg, between 10 mg / kg and 50 mg / kg, or between these values.

[0301] Advantageously, the dosage of the conjugates of the present invention is one level or order of magnitude lower than the dosage required for the therapeutic molecule to take effect when applied alone.

[0302] Suitablely, the conjugates of the present invention can be used in in vitro methods, and suitablely in vitro laboratory methods. Suitablely, the conjugates of the present invention can be used in in vitro methods for testing the efficacy of candidate therapeutic molecules. Suitablely, the in vitro method can be an assay. For example, the conjugates of the present invention can be used in splice correction assays, exon skipping assays, serum stability assays, cell viability assays, or assays for the restoration of truncated functional proteins.

[0303] Appropriately, the term "in vitro" is intended to include experiments performed with cultured cells, while the term "in vivo" is intended to include experiments performed with intact multicellular organisms.

[0304] In one embodiment, the conjugate is used to administer to a subject for subsequent in vitro cell evaluation.

[0305] toxicity

[0306] Using the conjugates of the present invention, which include connectors as defined in the first aspect, to link the carrier molecule and the therapeutic molecule advantageously reduces the toxicity of the conjugates. Therefore, the conjugates of the present invention are advantageously less toxic than existing conjugates, such as those discussed above and demonstrated in the examples.

[0307] Appropriately, after application of the conjugate of the present invention, one or more toxicity markers are significantly reduced compared to existing conjugates using currently available connectors.

[0308] Appropriate toxicity markers could be nephrotoxicity or hepatotoxicity markers.

[0309] Appropriate toxicity markers include KIM-1, NGAL, BUN, creatinine, alkaline phosphatase, alanine transferase, and aspartate aminotransferase.

[0310] When compared with conjugates using currently available connectors, the levels of at least one of KIM-1, NGAL, and BUN are appropriately reduced after application of the conjugate of the present invention.

[0311] When compared with conjugates using currently available connectors, the levels of each of KIM-1, NGAL, and BUN are appropriately reduced after application of the conjugates of the present invention.

[0312] Appropriately, the level of this or each marker is significantly reduced compared to existing conjugates.

[0313] Accordingly, compared with conjugates using currently available connectors, the level of said or each marker is reduced by up to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after application of the conjugates of the present invention.

[0314] Therefore, appropriately, the conjugates of the present invention have reduced nephrotoxicity compared to conjugates using currently available connectors.

[0315] KIM-1 / creatinine levels have been described as a useful indicator of the toxicity of CPP and CPP conjugates. In particular, KIM-1 / creatinine levels can be used to indicate the toxicity of arginine-rich CPP conjugates; Vaidya et al., Annu Rev Pharmacol Toxicol. 2008, 48, 463-493; Chaturvedi et al., Int. J. Biol. Sci. 2009, 5, 128-134; and Zhou et al., Sci Reports, 2016, 6, 38930.

[0316] Suitablely, the KIM-1 / creatinine level is reduced after application of the conjugate of the present invention compared to conjugates using currently available connectors. Suitablely, the KIM-1 / creatinine level is significantly reduced after application of the conjugate of the present invention compared to conjugates using currently available connectors.

[0317] Appropriately, compared with conjugates using currently available connectors, the KIM-1 / creatinine level was reduced by up to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, and 50% after application of conjugates containing the connectors of the present invention.

[0318] Advantageously, the conjugates exhibit significantly reduced toxicity compared to existing cell-penetrating peptides and their conjugates. In particular, KIM-1 / creatinine is a toxicity marker, and when using the conjugates of the present invention containing the defined linker, KIM-1 / creatinine is significantly reduced by up to 10, 20, 30, 50, 60, 70, 80, 90, 100, 110, and 120 times compared to existing conjugates.

[0319] A decreased KIM-1 / creatinine ratio indicates reduced kidney injury and increased glomerular filtration. It is believed that a decreased KIM-1 / creatinine ratio results from a reduction in the dedifferentiated proximal tubular epithelial cells frequently present in the kidneys following ischemic or toxic injury (Chaturvedi et al., 2009, Int. J. Biol. Sci.). The KIM-1 / creatinine ratio is widely used to assess the toxicity of therapeutic agents. Attached Figure Description

[0320] Some embodiments of the invention will now be described with reference to the following figures and tables, wherein:

[0321] Figure 1 The comparison with 0.9% saline and currently available therapeutic antisense PMOs is shown. DMD Compared to conjugated peptide carriers (R6Gly- and Pip9b2-), the therapeutic antisense PMO was administered via different linkers at a single dose of 30 mg / kg. DMD Relative levels of urinary kidney injury marker-1 (KIM-1) normalized to urinary creatinine, measured in the urine of C57BL / 6 mice on days 2 and 7 after conjugation of DPEP3.1 peptide (error bars: mean with SEM, n = 3–10).

[0322] Figure 2: Showing the effects of a single 30 mg / kg intravenous bolus administration of therapeutic antisense PMO via different connectors in C57BL / 6 mice. DMD The in vivo efficacy of the conjugated DPEP3.1 peptide in (A) tibialis anterior muscle, (B) diaphragm, and (C) cardiac muscle. Exon skipping efficacy of dystrophin (exon 23) was measured by qPCR 7 days post-administration. Exon skipping efficacy was compared with a 0.9% saline control and with currently available therapeutic antisense PMOs. DMD Compared to conjugated peptide carriers (R6Gly- and Pip9b2-), DPEP3.1d-PMO DMD Outliers indicate injection failure. (Error bars: average values ​​with SEM, n = 3-10).

[0323] Figure 3 The comparison with 0.9% saline and currently available therapeutic antisense PMOs is shown. DMD Compared to conjugated peptide carriers (R6Gly- and Pip9b2-), these peptides, administered at single doses of 10 mg / kg, 30 mg / kg, or 50 mg / kg, via different linkers with therapeutic antisense PMOs. DMD Relative levels of urinary kidney injury marker-1 (KIM-1) normalized to urinary creatinine, measured in the urine of C57BL / 6 mice on days 2 and 7 after conjugation of the DPEP1.9 peptide (error bars: mean with SEM, n = 3–10).

[0324] Figure 4: Showing the effects of different connectors and therapeutic antisense PMO after a single intravenous bolus administration of 10 mg / kg, 30 mg / kg, or 50 mg / kg in C57BL / 6 mice. DMDThe in vivo efficacy of the conjugated DPEP1.9 peptide in (A) tibialis anterior muscle, (B) diaphragm, and (C) cardiac muscle. Exon skipping efficacy of dystrophin (exon 23) was measured by qPCR 7 days post-administration. Exon skipping efficacy was compared with a 0.9% saline control and with currently available therapeutic antisense PMOs. DMD Comparison of conjugated peptide carriers (R6Gly- and Pip9b2-) (error bars: mean with SEM, n = 3–10).

[0325] Figure 5 and Figure 7 This study demonstrates how different DPEP1 / 3-[CAG]7 conjugates, using linkers a, b, and d, corrected splicing defects of the Mbnl1-dependent transcript in myoblasts derived from DM1 patients with 2600 CTG repeats in the DMPK gene at various concentrations.

[0326] Figure 6 This study demonstrates how different DPEP1 / 3-[CAG]7PMO conjugates, using linkers a, b, and d, corrected splicing defects of DMD transcripts in DM1 myoblasts derived from DM1 patients with 2600 repeats in the DMPK gene at various concentrations in vitro.

[0327] Figure 8 The image shows the percentage of myoblast survival in DM1 patient myoblasts with 2600 CTG replicates transfected 48 hours after using different doses of DPEP1 / 3-[CAG]7 conjugates with connectors a, b, and d. The concentration of the conjugate can be increased several times from therapeutic levels without causing cell death.

[0328] Figure 9 The image shows the percentage of hepatocyte survival after transfection with different DPEP1 / 3-[CAG]7 conjugates using adapters a, b, and d at 40 μM. Unlike the Pip6a conjugate, the concentration of the conjugate can be increased several times from therapeutic levels without causing cell death.

[0329] Figure 10 and Figure 11 This study presents urinary toxicological markers on days 2 and 7 after injection of different DPEP1 / 3-[CAG]7PMO conjugates in female C57BL6 mice, measured by ELISA (R&D cat#MKM100), with samples diluted to fit the standard curve. Values ​​were normalized to urinary creatinine levels (Harwell) to calculate urinary protein concentrations. KIM-1 levels were similar to the saline control injection compared to the fold increase induced by existing Pip series peptide carriers.

[0330] Figure 12 and Figure 13 Toxicological markers evaluated in serum from female C57BL6 mice (8–10 weeks old, n = 5 per group) that received an IV (tail vein) bolus of different DPEP1 / 3-[CAG]7PMO conjugates with different connectors. Serum was collected on day 7 post-injection, compared to saline. On day 7 post-injection, all levels were similar to those of the saline control.

[0331] Throughout the description and claims of this specification, the words “comprising” and “including” and variations thereof mean “including, but not limited to”, and they are not intended to (and do not) exclude other parts, additives, components, integers, or steps. Throughout the description and claims of this specification, the singular form includes the plural form unless the context requires otherwise. In particular, where indefinite articles are used, the invention should be understood to include both the plural and the singular, unless the context requires otherwise.

[0332] Features, integers, properties, compounds, chemical parts, or groups described in connection with a particular aspect, embodiment, or example of the invention should be understood to be applicable to any other aspect, embodiment, or example described herein, unless incompatible therewith. All features disclosed in this specification (including any appended claims, abstract, and drawings) and / or all steps of any method or process so disclosed may be combined in any arbitrary combination, except that at least some of these features and / or steps are mutually exclusive combinations. The invention is not limited to the details of any of the foregoing embodiments.

[0333] This invention extends to any novel one or any novel combination of features disclosed in this specification (including any appended claims, abstract, and drawings), or to any novel one or any novel combination of steps of any method or process so disclosed. Readers should note all papers and documents related to this application that were filed concurrently with or prior to this specification, which are publicly available together with this specification, and the contents of all such papers and documents are incorporated herein by reference. Example

[0334] 1. Materials and Methods

[0335] 1.1 Materials

[0336] 9-fluorenylmethoxycarbonyl (Fmoc) protected L-amino acids, benzotriazol-1-yl-oxy-tripyrrolidinyl phosphate (PyBOP), and Rink amide resin (0.46 mmol·g) obtained from Merck (Hohenbrunn, Germany) -1) and Fmoc-β-Ala-OH pre-filled Wang's resin (0.19 or 0.46 mmol·g) -1 Tentagel hydroxytriphenylmethyl resin was purchased from Rapp Polymere (Tuebingen, Germany). HPLC-grade acetonitrile, methanol, and synthetic-grade N-methyl-2-pyrrolidone (NMP) were purchased from Fisher Scientific (Loughborough, UK). Peptide synthesis-grade N,N-dimethylformamide (DMF) and diethyl ether were obtained from VWR (Leicestershire, UK). Piperidine and trifluoroacetic acid (TFA) were obtained from Alfa Aesar (Heysham, UK). PMO was purchased from Gene Tools Inc. (Philomath, USA). MALDI-TOF mass spectrometry analysis was performed using a Voyager DE Pro BioSpectrometry (Applied Biosystems, Cheshire, UK) workstation. 10 mg / mL of acetonitrile was added to water. -1 α-Cyano-4-hydroxycinnamic acid or sinapic acid stock solutions were used as matrices. Analytical and semi-preparative HPLC were performed on a Varian 940-LC HPLC system (Yarnton, UK). DMEM medium (31966047), fetal bovine serum (FBS) (10270106), antibiotic antifungal solution (A5955), ethidium bromide (15585011), 2x ReddyMix PCR Master Mix (AB0575DCLDB), M-MLV first-chain synthesis system (28025013), and TRIzol reagent (15596026) were purchased from Thermo Fisher Scientific. RealTime-Glo™ MT cell viability assay (G9711) was used. Total RNA purification kit (AS1050) was purchased from Promega. Myoblasts were cultured using PromoCell Skeletal Muscle Cell Growth Medium Kit (C-23160). Insulin (91077C) and agarose (A9539) were from Sigma-Aldrich. DNA marker-HyperLadder 50bp (BIO-33039) was from BioLine Reagents. All primers were ordered through IDT. For urine collection, mice were housed individually in metabolic cages at Tecniplast, UK, and a urinary biomarker ELISA (MKM100) for kidney injury marker 1 (KIM-1) was obtained from R&D. Unless otherwise specified, all other reagents were obtained from Sigma-Aldrich (UK).

[0337] 1.2 Synthesis of peptide-PMO conjugates

[0338] 1.2.1 Synthesis of peptide variants using a microwave synthesizer

[0339] Using CEM Liberty Blue TM Peptides were synthesized in 100 μmol increments using a microwave peptide synthesizer (Buckingham, UK) and the Fmoc chemical method, following the manufacturer's recommendations. Peptides synthesized with glutamic acid or succinic acid as linkers were synthesized with Rink amide resin to provide an amide at the carboxyl terminus of the peptide after TFA cleavage. Peptides with a β-alanine linker were synthesized using pre-packed Wang's resin. A complete list of peptides synthesized using their method and linkers is summarized in Table 1. The side-chain protecting groups used were unstable to TFA treatment, and peptides were synthesized using a 5-fold excess of Fmoc-protected amino acids (0.25 mmol), which were activated with PyBOP (5-fold excess) in the presence of DIPEA. Piperidine (20%, v / v in DMF) was used to remove the N-Fmoc protecting groups. The coupling was carried out at 75°C for 5 minutes at 60 W microwave power, except for arginine residues, each of which was coupled twice. Each deprotection reaction was carried out twice at 75°C, once for 30 seconds and then once for 3 minutes at 35 W microwave power. Once synthesis was complete, the resin was washed with DMF (3 x 50 mL), and the N-terminus of the confined peptide was acetylated with acetic anhydride in the presence of DIPEA for 15 min at room temperature. After N-terminal acetylation, the peptide resin was washed with DMF (3 x 20 mL) and DCM (3 x 20 mL). For DPEP peptides with succinic acid at the N-terminus, no N-terminal acetylation was performed. Instead, the free N-terminus of the peptide was treated with succinic anhydride in the presence of DIPEA at room temperature for 30 min, followed by washing with DMF (3 x 20 mL). For DPEP peptides carrying glutamic acid as a linker at the N-terminus, the N-terminus was acetylated as described above, but the PMO linkage was performed on the side chain carboxyl group.

[0340] 1.2.2 Synthesis of peptide variants using the Intavis Multipep synthesizer

[0341] Peptides with γ-aminobutyric acid (GABA) linkers were synthesized at room temperature on Tentagel Cl-triphenylmethyl resin using an Intavis Multipep synthesizer and Fmoc Chemistry, following the manufacturer's recommendations. Acetyl chloride was used from... Preparation of hydroxytriphenylmethyl resin Cl-triphenylmethyl resin. Briefly, the resin (1 g) was washed with DMF (2 x 10 mL), dry DCM (3 x 10 mL), and dry toluene (3 x 10 mL), and transferred to a round-bottom tube fitted with a condenser. Sufficient toluene was added to cover the resin, followed by dropwise addition of acetyl chloride (1 mL·g). -1 The resin (total volume 1 mL) was heated at 60–70 °C with gentle stirring for 3 hours. After heating, the resin was cooled to room temperature and then thoroughly washed with toluene (5 x 15 mL), DMF (5 x 15 mL), and finally with dry DCM (3 x 15 mL). Fmoc-γ-aminobutyric acid (3 equivalents) in DCM with DIEA (8 equivalents) was then loaded into the resin for 15 minutes, followed by the addition of additional DIEA (4 equivalents) and mixing for a total of 1 hour. After 1 hour, the resin was end-capped with MeOH (0.8 mL·g⁻¹) for 15 minutes, then washed with DMF (5 × 10 mL) and DCM (5 × 15 mL). The yield and loading of the resin were determined by UV / Vis spectrophotometer at 304 nm to be 0.41 mmol·g⁻¹, and the resin was used immediately.

[0342] Typically, peptides are synthesized on a 100 μmol scale using standard Fmoc amino acids with side-chain protecting groups unstable to TFA, and these peptides are synthesized using a 5-fold excess of Fmoc-protected amino acids (0.50 mmol), which are activated with PyBOP (5-fold excess) in the presence of 4-methylmorpholine. A double-coupling step is used, followed by end-capping with acetic anhydride after each step. The N-Fmoc protecting group is removed using piperidine (20%, v / v in DMF). Each deprotection cycle is performed twice at room temperature for 10 minutes each time. Once synthesis is complete, the resin is washed with DMF (3 x 50 mL) and the N-terminus of the confined peptide is acetylated with acetic anhydride in the presence of DIPEA at room temperature for 15 min. After N-terminal acetylation, the peptide resin is washed with DMF (3 x 20 mL) and DCM (3 x 20 mL).

[0343]

[0344]

[0345] Table 1. Synthetic methods and resins used for peptides with different linkers, and the resulting C-terminal modifications.

[0346] 1.2.3 Peptides were separated and purified from solid supports by semi-preparative HPLC.

[0347] The peptide was separated from the solid support by treatment with a separation mixture consisting of TFA / H2O / triisopropylsilane (TIPS) (95:2.5:2.5:10 mL) at room temperature for 3 hours. Excess TFA was removed by purging with nitrogen. The separated peptide was precipitated by adding ice-cold diethyl ether and centrifuged at 3000 rpm for 5 min. The crude peptide precipitate was washed three times with cold diethyl ether (3 × 40 mL) and purified by RP-HPLC using a Varian 940-LC HPLC system equipped with a 445-LC amplification module and a 440-LC fraction collector. The peptide was purified by semi-preparative HPLC on an RP-C18 column (10 x 250 mm, Phenomenex Jupiter) using a linear gradient of CH3CN in 0.1% TFA / H2O (0-99%, 0.1% TFA in CH3CN) at a flow rate of 15 mL / min. -1 The time exceeded 15 minutes. Detection was performed at 220nm and 260nm.

[0348]

[0349] Table 2. Peptide sequences synthesized for testing in embodiments with different connectors and junctions. a The linkers are listed in the form of their individual amino acid abbreviations. b The linker is relative to the peptide, with the C-terminus being the carboxyl terminus and the N-terminus being the amino terminus. A sequence ID number indicates a peptide sequence without any additional N- or C-terminal modifications (e.g., linkers).

[0350] 1.2.4 Synthesis of peptide-PMO conjugates

[0351] The 25-mer PMO antisense sequence targeting exon 23 of mouse dystrophy protein (GGCCAAACCTCGGCTTACCTGAAAT (SEQ ID)) was used. NO:74). Depending on the linker site, the peptide is conjugated to the 3' end of PMO via its C-terminal carboxyl group or N-terminal amino group. This is achieved by using 2.3 and 2 equivalents of PyBOP and HOAt in NMP, respectively, with 2.3 equivalents of DIPEA relative to the peptide and 2.5 times the excess peptide relative to PMO dissolved in DMSO. Typically, PyBOP (76.6 μL of 0.3 M NMP solution), HOAt (66.7 μL of 0.3 M NMP solution), DIPEA (4.0 μL), and PMO (4 μmol, 400 μL of 10 mM DMSO solution) are added to a solution of peptide (10 μmol) dissolved in N-methylpyrrolidone (NMP, 100 μL). The mixture is incubated at 40 °C for 2 hours, and the reaction is quenched by adding H2O (1 mL). The reaction is carried out in a sodium phosphate buffer (25 mM, pH 10) containing 20% ​​CH3CN. In 7.0), a linear gradient of sodium chloride (0 to 1 M) was used at a rate of 6 mL / min. -1 The reaction was purified on a cation exchange chromatography column (Resource S 6 mL, GE Healthcare) at a flow rate of [unspecified value]. The fraction collected after ion exchange was filtered using an ultra-15 3K centrifugal filter to remove excess salt from the peptide-PMO (P-PMO) conjugate. The conjugate was lyophilized and analyzed by MALDI-TOF. Before use, the conjugate was dissolved in sterile water and filtered through a 0.22 μm cellulose acetate membrane. The concentration of P-PMO was determined by the molar absorbance of the conjugate at 265 nm in 0.1 M HCl solution. The overall yield (Table 3) based on P-PMO was 26-64%.

[0352]

[0353]

[0354] Table 3. Yields of the large-scale synthesized P-PMO conjugates used for in vivo analysis (yields were calculated by UV-Vis spectroscopy and based on the extinction coefficient of PMO). The purity of P-PMO was greater than 95% as determined by normal-phase HPLC at 220 nm and 260 nm. a The PMO used for peptide conjugation has the following sequence: 5'-GGCCAAACCTCGGCTTACCTGAAAT-3'. b PMO connections are given here in bold italics, and connectors are given in parentheses.

[0355] The following comparative conjugates were also synthesized / obtained and the same PMO was conjugated to peptides using comparative linkers.

[0356]

[0357] Table 4: Comparison of peptides

[0358] 1.3 Quantitative Analysis and Reconstruction of P-PMO

[0359] P-PMO was dissolved in RNase-free water. From this solution, aliquots were diluted 100-fold in 0.1 M HCl and measured at 265 nm using UV-VIS. The concentration was determined using Beer-Lambert's law.

[0360]

[0361] Before use, thaw P-PMO to room temperature (if pre-frozen) and briefly vortex, then incubate at 37°C for 30 minutes. Subsequently, sonicate P-PMO aliquots in an ultrasonic bath for 5 minutes. Finally, briefly vortex and pulse-rotate the P-PMO.

[0362] The injection solution is prepared by mixing P-PMO diluted in RNase-free water to the desired therapeutic concentration with 9% saline (to a final concentration of 0.9% saline).

[0363] 1.4 In vivo P-PMO treatment evaluation

[0364] 1.4.1 Systemic administration of P-PMO

[0365] All animal experiments were conducted at the Department of Biomedical Sciences, Oxford University, under a Home Office project license (UK) and in accordance with the Animals (Scientific Procedures) Act 1986 and institutional ethics review. Mice were housed in designated pathogen-free disease facilities; the environment was controlled for temperature and humidity, and subjected to 12-hour light-dark cycles. All animals had free access to commercially available rodent food and water.

[0366] The experiment was conducted on 8-10 week old female C57BL / 6 mice. Mice received a single intravenous bolus injection via tail vein of 0.9% saline, 10 mg / kg, 30 mg / kg, or 50 mg / kg of P-PMO. One week after injection, the mice were sacrificed, and the tibialis anterior muscle, diaphragm, and myocardium were removed, rapidly frozen on dry ice, and stored at -80°C.

[0367] 1.4.2 Toxicological assessment of peptide-PMO

[0368] Following intravenous administration of P-PMO (see Section 1.4.1), urine was noninvasively collected under refrigeration on days 2 and 7 post-administration, and then placed in a metabolic cage for 20 hours. Blood was collected from the jugular vein on day 7 during necropsy, and the blood was graded and serum was collected. Tibial anterior muscle, diaphragm, and cardiac tissue were collected on day 7 during necropsy.

[0369] After appropriately diluting urine to conform to a standard curve, the level of kidney injury molecule 1 (KIM-1) in urine was quantified by ELISA. KIM-1 values ​​were normalized to urinary creatinine levels, which were quantified at the MRC Harwell Institute (Mary Lyon Centre, Oxfordshire, UK).

[0370] 1.4.3 qPCR analysis of P-PMO-induced exon skipping

[0371] Seven days after administration, quantification of P-PMO-induced exon skipping was performed in the tibialis anterior (Ta), diaphragm, and myocardium. Briefly, RNA was extracted from homogenized tissues using a Trizol-based extraction method, and cDNA was synthesized using random primers. Primers / probes were synthesized via Integrated DNA Technologies and designed to amplify regions spanning exons 23–24 representing non-skipped products (mDMD23–24, see Table 4), or to specifically amplify transcripts lacking exon 23 using probes spanning the exon 22 and 24 boundary (mDMD22–24). The levels of individual transcripts were determined by skipping and non-skipped transcripts and expressed as a percentage of skipped transcripts relative to all (skipped and non-skipped) transcripts (sequences see Table 5).

[0372]

[0373]

[0374] Table 5. Primer and probe sequences used for quantifying exon skipping of mouse dystrophin (exon 23) by qPCR.

[0375] 2. Other embodiments

[0376] Synthesis of peptide-PMO conjugates

[0377] As previously described, peptides were synthesized and conjugated with PMO. The PMO sequence (5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81) targeting the CUG extended repeat sequence was purchased from Gene Tools LLC and used to prepare other conjugates.

[0378] Cell culture and peptide-PMO treatment.

[0379] Immortalized myoblasts from healthy individuals or DM1 patients with 2600 CTG replicates were cultured in growth medium consisting of an M199:DMEM mixture (1:4 ratio, Life Technologies), supplemented with 20% FBS (Life Technologies), 50 μg / ml gentamicin (Life Technologies), 25 μg / ml fetoglobulin, 0.5 ng / ml bFGF, 5 ng / ml EGF, and 0.2 μg / ml dexamethasone (Sigma-Aldrich). For myoblasts, myogenic differentiation was induced by switching the confluenced cell culture to DMEM supplemented with 5 μg / ml insulin (Sigma-Aldrich). For treatment, WT or DM1 cells were differentiated for 4 days. The medium was then replaced with fresh differentiation medium containing peptide-PMO at concentrations of 1, 2, 5, 10, 20, or 40 μM. Cells were harvested for analysis 48 hours after treatment. Two days after transfection of human hepatocytes with peptide-PMO at a concentration of 40 μM or in myoblasts at concentrations of 1, 2, 5, 10, 20 or 40 μM, cell viability was quantified using a fluorescence-based assay (Promega).

[0380] RNA isolation, RT-PCR

[0381] For human cells: Prior to RNA extraction, cells were lysed at 55°C for 45 min in proteinase K buffer (500 mM NaCl, 10 mM Tris-HCl, pH 7.2, 1.5 mM MgCl2, 10 mM EDTA, 2% SDS, and 0.5 mg / ml proteinase K). Total RNA was isolated using TriReagent according to the manufacturer's protocol. One microgram of RNA was reverse transcribed using the M-MLV first-strand synthesis system (Life Technologies) according to the manufacturer's instructions, for a total volume of 20 μL. Subsequently, one microliter of cDNA preparation was used for semi-quantitative PCR analysis according to a standard protocol (ReddyMix, Thermo Scientific). PCR amplification was performed for 25–35 cycles within the linear amplification range for each gene. PCR products were separated on 1.5–2% agarose gels, stained with ethidium bromide, and quantified using ImageJ software. The exon inclusion ratio was quantified as the percentage of inclusion relative to the total intensity of the isoform signal. For quantification of mRNA expression, real-time PCR was performed according to the manufacturer's instructions. The PCR cycle consisted of a 15-minute denaturation step, followed by 50 cycles, with denaturation at 94°C for 15 seconds, annealing at 58°C for 20 seconds, and extension at 72°C for 20 seconds.

[0382] Table 6: Primers used for PCR

[0383]

[0384] Animal experiments and ASO injection.

[0385] The experiments were conducted at Oxford University in accordance with UK law. Intravenous administration to HSA-LR C57BL / 6 mice was performed via single or repeated administration through the tail vein. Peptide-PMO-CAG7 was diluted in 0.9% saline at doses of 30, 12.5, 7.5, and 5 mg / kg and administered at volumes of 5–6 μL / g body weight. KIM-1 levels in female C57BL6 mice were measured by ELISA (R&Dcat#MKM100), where samples were diluted to conform to a standard curve. Values ​​were normalized to urinary creatinine levels (Harwell) to calculate urinary protein concentration.

[0386] Table 7: The recovery time of C57BL6 mice after injection of DPEP-based [CAG]7PMO conjugates was shorter than that after injection of conjugates formed by existing peptide carriers (such as Pip6a).

[0387] sequence list <110> Oxford University Technology Innovation Ltd. UK Research and Innovation Organization <120> connector <130> P266682GB1 <160> 86 <170> PatentIn version 3.5 <210> 1 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <400> 1 Arg Xaa Arg Arg Xaa Arg 1 5 <210> 2 <211> 9 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <400> 2 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg 1 5 <210> 3 <211> 12 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (11)..(11) <223> X is aminocaproic acid. <400> 3 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg 1 5 10 <210> 4 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <400> 4 Arg Xaa Arg Arg Xaa Arg 1 5 <210> 5 <211> 9 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is bAla <400> 5 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg 1 5 <210> 6 <211> 12 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is bAla <220> <221> MISC_FEATURE <222> (11)..(11) <223> X is bAla <400> 6 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg 1 5 10 <210> 7 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 7 Arg His Arg Arg His Arg 1 5 <210> 8 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Artificial sequence <400> 8 Arg His Arg Arg His Arg Arg His Arg 1 5 <210> 9 <211> 12 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 9 Arg His Arg Arg His Arg Arg His Arg Arg His Arg 1 5 10 <210> 10 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 10 Gly Phe Thr Gly Pro Leu 1 5 <210> 11 <211> 5 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 11 Phe Gln Ile Leu Tyr 1 5 <210> 12 <211> 5 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 12 Tyr Gln Phe Leu Ile 1 5 <210> 13 <211> 5 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 13 Ile Leu Phe Gln Tyr 1 5 <210> 14 <211> 4 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 14 Phe Gln Ile Tyr 1 <210> 15 <211> 5 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 15 Trp Trp Pro Trp Trp 1 5 <210> 16 <211> 4 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 16 Trp Pro Trp Trp 1 <210> 17 <211> 4 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 17 Trp Trp Pro Trp 1 <210> 18 <211> 4 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 18 Ile Leu Phe Gln 1 <210> 19 <211> 4 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 19 Ile Leu Ile Gln 1 <210> 20 <211> 7 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 20 Ile Lys Ile Leu Phe Gln Asn 1 5 <210> twenty one <211> 7 <212> PRT <213> Artificial sequence <220> <223> peptides <400> twenty one Ile His Ile Leu Phe Gln Asn 1 5 <210> twenty two <211> 7 <212> PRT <213> Artificial sequence <220> <223> peptides <400> twenty two Ile Arg Ile Leu Phe Gln Asn 1 5 <210> twenty three <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> twenty three Ile Ile Leu Phe Gln Asn 1 5 <210> twenty four <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> twenty four Lys Ile Leu Phe Gln Asn 1 5 <210> 25 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 25 His Ile Leu Phe Gln Asn 1 5 <210> 26 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 26 Arg Ile Leu Phe Gln Asn 1 5 <210> 27 <211> 5 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 27 Ile Leu Phe Gln Asn 1 5 <210> 28 <211> 5 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 28 His Leu Ile Gln Asn 1 5 <210> 29 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 29 Lys Ile Leu Ile Gln Asn 1 5 <210> 30 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 30 Lys Ile Leu Ile Gln Tyr 1 5 <210> 31 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 31 His Ile Leu Ile Gln Asn 1 5 <210> 32 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 32 Arg Ile Leu Ile Gln Asn 1 5 <210> 33 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 33 His Ile Leu Ile Gln Tyr 1 5 <210> 34 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 34 Arg Ile Leu Ile Gln Tyr 1 5 <210> 35 <211> 5 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 35 Ile Leu Ile Gln Asn 1 5 <210> 36 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Artificial sequence <400> 36 Ile Leu Ile Gln Tyr 1 5 <210> 37 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Artificial sequence <400> 37 Arg Arg Arg Arg Arg 1 5 <210> 38 <211> 6 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 38 Arg Arg Arg Arg Arg Arg 1 5 <210> 39 <211> 7 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 39 Arg Arg Arg Arg Arg Arg Arg 1 5 <210> 40 <211> 8 <212> PRT <213> Artificial sequence <220> <223> peptides <400> 40 Arg Arg Arg Arg Arg Arg Arg Arg 1 5 <210> 41 <211> 12 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (11)..(11) <223> X is bAla <400> 41 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg 1 5 10 <210> 42 <211> 13 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is a bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (11)..(11) <223> X is a bAla <220> <221> MISC_FEATURE <222> (13)..(13) <223> X is aminocaproic acid. <400> 42 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Xaa 1 5 10 <210> 43 <211> 13 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (11)..(11) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (13)..(13) <223> X is aminocaproic acid. <400> 43 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Xaa 1 5 10 <210> 44 <211> 17 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <400> 44 Arg Xaa Arg Arg Xaa Arg Arg Phe Gln Ile Leu Tyr Arg Xaa Arg Xaa 1 5 10 15 Arg <210> 45 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 45 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 46 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 46 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 47 <211> 17 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (13)..(13) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <400> 47 Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa Arg Arg Xaa 1 5 10 15 Arg <210> 48 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is bAla <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is bAla <400> 48 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 49 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 49 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 50 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is aminocaproic acid. <400> 50 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Arg Xaa Arg 20 <210> 51 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 51 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa 20 <210> 52 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is aminocaproic acid. <400> 52 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Arg Xaa Arg 20 <210> 53 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 53 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa 20 <210> 54 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 54 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Leu Phe Gln Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 55 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 55 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Tyr Gln Phe Leu Ile Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 56 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 56 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Gln Phe Leu Ile Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 57 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (15)..(15) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is bAla <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is aminocaproic acid. <400> 57 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Gln Phe Leu Ile Arg Xaa Arg 1 5 10 15 Xaa Arg Xaa Arg 20 <210> 58 <211> 19 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is bAla <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is aminocaproic acid. <400> 58 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Gln Phe Leu Arg Xaa Arg Xaa 1 5 10 15 Arg Xaa Arg <210> 59 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (15)..(15) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is bAla <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is aminocaproic acid. <400> 59 Arg Xaa Arg Arg Xaa Arg Arg Xaa Tyr Arg Phe Leu Ile Arg Xaa Arg 1 5 10 15 Xaa Arg Xaa Arg 20 <210> 60 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (18)..(18) <223> X is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> X is aminocaproic acid. <400> 60 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Phe Gln Ile Leu Tyr Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 61 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (15)..(15) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is bAla <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is aminocaproic acid. <400> 61 Arg Xaa Arg Arg Xaa Arg Arg Xaa Tyr Arg Phe Arg Leu Ile Xaa Arg 1 5 10 15 Xaa Arg Xaa Arg 20 <210> 62 <211> 20 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (15)..(15) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is bAla <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is aminocaproic acid. <400> 62 Arg Xaa Arg Arg Xaa Arg Arg Xaa Ile Leu Phe Arg Tyr Arg Xaa Arg 1 5 10 15 Xaa Arg Xaa Arg 20 <210> 63 <211> twenty two <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is bAla <220> <221> MISC_FEATURE <222> (21)..(21) <223> X is aminocaproic acid. <400> 63 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Ile Tyr Gln Phe Leu Ile Arg 1 5 10 15 Xaa Arg Xaa Arg Xaa Arg 20 <210> 64 <211> twenty four <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (7)..(7) <223> X is bAla <220> <221> MISC_FEATURE <222> (10)..(10) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (12)..(12) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (15)..(15) <223> X is bAla <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is bAla <400> 64 Tyr Gln Phe Leu Ile Arg Xaa Arg Arg Xaa Arg Xaa Arg Xaa Xaa Arg 1 5 10 15 Xaa Arg Xaa Tyr Gln Phe Leu Ile 20 <210> 65 <211> twenty two <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (7)..(7) <223> X is bAla <220> <221> MISC_FEATURE <222> (10)..(10) <223> X is bAla <220> <221> MISC_FEATURE <222> (12)..(12) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is bAla <400> 65 Tyr Gln Phe Leu Ile Arg Xaa Arg Arg Xaa Arg Xaa Arg Xaa Arg Arg 1 5 10 15 Xaa Tyr Gln Phe Leu Ile 20 <210> 66 <211> twenty four <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (7)..(7) <223> X is bAla <220> <221> MISC_FEATURE <222> (10)..(10) <223> X is bAla <220> <221> MISC_FEATURE <222> (12)..(12) <223> X is bAla <220> <221> MISC_FEATURE <222> (14) (15) <223> X is bAla <220> <221> MISC_FEATURE <222> (17)..(17) <223> X is aminocaproic acid. <220> <221> MISC_FEATURE <222> (19)..(19) <223> X is bAla <400> 66 Tyr Gln Phe Leu Ile Arg Xaa Arg Arg Xaa Arg Xaa Arg Xaa Xaa Arg 1 5 10 15 Xaa Arg Xaa Tyr Gln Phe Leu Ile 20 <210> 67 <211> 17 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is bAla <400> 67 Arg Xaa Arg Arg Xaa Arg Arg Phe Gln Ile Leu Tyr Arg Xaa Arg Xaa 1 5 10 15 Arg <210> 68 <211> 17 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is bAla <400> 68 Arg Xaa Arg Arg Xaa Arg Arg Tyr Gln Phe Leu Ile Arg Xaa Arg Xaa 1 5 10 15 Arg <210> 69 <211> 17 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is bAla <400> 69 Arg Xaa Arg Arg Xaa Arg Arg Ile Leu Phe Gln Tyr Arg Xaa Arg Xaa 1 5 10 15 Arg <210> 70 <211> 15 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (12)..(12) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <400> 70 Arg Xaa Arg Arg Xaa Arg Phe Gln Ile Leu Tyr Xaa Arg Xaa Arg 1 5 10 15 <210> 71 <211> 17 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is bAla <400> 71 Arg Xaa Arg Arg Xaa Arg Arg Phe Gln Ile Leu Tyr Arg Xaa His Xaa 1 5 10 15 His <210> 72 <211> 17 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (14)..(14) <223> X is bAla <220> <221> MISC_FEATURE <222> (16)..(16) <223> X is bAla <400> 72 Arg Xaa Arg Arg Xaa Arg Arg Phe Gln Ile Leu Tyr His Xaa His Xaa 1 5 10 15 Arg <210> 73 <211> 16 <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> X is bAla <220> <221> MISC_FEATURE <222> (5)..(5) <223> X is bAla <220> <221> MISC_FEATURE <222> (13)..(13) <223> X is bAla <220> <221> MISC_FEATURE <222> (15)..(15) <223> X is bAla <400> 73 Arg Xaa Arg Arg Xaa Arg Phe Gln Ile Leu Tyr Arg Xaa His Xaa His 1 5 10 15 <210> 74 <211> 25 <212> DNA <213> Artificial sequence <220> <223> 25-mer PMO antisense sequence of exon 23 of mouse dystrophy protein <400> 74 ggccaaacct cggcttacct gaaat 25 <210> 75 <211> 20 <212> DNA <213> Artificial sequence <220> <223> mDMD (exons 23-24) forward primer (5'-3') <400> 75 caggccattc ctctttcagg 20 <210> 76 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> mDMD (exons 23-24) reverse primer (5'-3') <400> 76 gaaactttcc tcccagttgg t 21 <210> 77 <211> 29 <212> DNA <213> Artificial sequence <220> <223> mDMD (exon 23-24) probe <220> <221> misc_feature <222> (1)..(1) <223> Labelled with FAM <220> <221> misc_feature <222> (9) (10) <223> Connected via internal quencher ZEN <220> <221> misc_feature <222> (29)..(29) <223> Marked with IABkFQ <400> 77 tcaacttcag ccatccattt ctgtaaggt 29 <210> 78 <211> 30 <212> DNA <213> Artificial sequence <220> <223> mDMD (exon 22-24) forward primers (5'-3') <400> 78 ctgaatatga aataatggag gagagactcg 30 <210> 79 <211> 25 <212> DNA <213> Artificial sequence <220> <223> mDMD (exon 22-24) reverse primer (5'-3') <400> 79 cttcagccat ccatttctgt aaggt 25 <210> 80 <211> 19 <212> DNA <213> Artificial sequence <220> <223> mDMD (exon 22-24) probe <220> <221> misc_feature <222> (1)..(1) <223> Marked with FAM <220> <221> misc_feature <222> (9) (10) <223> Connected via internal quencher ZEN <220> <221> misc_feature <222> (9) (10) <223> Connected via internal quencher ZEN <220> <221> misc_feature <222> (19)..(19) <223> Marked with IABkFQ <400> 80 atgtgattct gtaatttcc 19 <210> 81 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> PMO sequences targeting CUG amplification of repetitive sequences <400> 81 cagcagcagc agcagcagca g 21 <210> 82 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> peptides <220> <221> MISC_FEATURE <222> (2)..(2) <223> x is aminocaproic acid <220> <221> MISC_FEATURE <222> (5)..(5) <223> x is bAla <220> <221> MISC_FEATURE <222> (8)..(8) <223> x is aminocaproic acid <220> <221> MISC_FEATURE <222> (16)..(16) <223> x is aminocaproic acid <220> <221> MISC_FEATURE <222> (18)..(18) <223> x is bAla <220> <221> MISC_FEATURE <222> (20)..(20) <223> x is aminocaproic acid <400> 82 Arg Xaa Arg Arg Xaa Arg Arg Xaa Arg Tyr Gln Phe Leu Ile Arg Xaa 1 5 10 15 Arg Xaa Arg Xaa Arg 20 <210> 83 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Primer Mbnl1.F <400> 83 gctgcccaat accaggtcaa c 21 <210> 84 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Primer Mbnl1.R <400> 84 tggtgggaga aatgctgtat gc 22 <210> 85 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Primer DMD.F <400> 85 ttagaggagg tgatggagca 20 <210> 86 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Primer DMD.R <400> 86 gatactaagg actccatcgc 20

Claims

1. A conjugate or a pharmaceutically acceptable salt thereof, having the following structure: ; The carrier is a peptide, which is a sequence selected from SEQ ID NO: 70, SEQ ID NO: 71 or SEQ ID NO: 73, wherein the N-terminus of the peptide is N-acetylated or unmodified; The therapeutic molecule is an antisense oligonucleotide, wherein the antisense oligonucleotide is a PMO with the sequence 5'-GGCCAAACCTCGGCTTACCTGAAAT-3', which is conjugated at its 3' end.

2. The conjugate according to claim 1, wherein the sequence of the peptide consists of the sequence of SEQ ID NO: 70 and the N-terminus of the peptide is N-acetylated.

3. The conjugate according to claim 1, wherein the sequence of the peptide consists of the sequence of SEQ ID NO: 71 and the N-terminus of the peptide is N-acetylated.

4. The conjugate according to claim 1, wherein the sequence of the peptide consists of the sequence of SEQ ID NO: 73 and the N-terminus of the peptide is N-acetylated.

5. A pharmaceutical composition comprising the conjugate according to any one of claims 1-4.

Citation Information

Patent Citations

  • Cell-penetrating peptides

    GB201812972D0

  • Cell-penetrating peptides

    GB201812980D0

  • Peptide oligonucleotide conjugates

    US20160237426A1

  • Tissue specific peptide conjugates and methods

    WO2009005793A2

  • peptides

    WO2009147368A1